Q-omics provides the consensus-scored KIR2DL4 profile across patient tissues and cancer cell-line models. KIR2DL4 expression is associated with patient survival in 30 of 34 cancer types, with the highest sampling consensus in SKCM. Among the 18 cancer types available for tumor–normal comparison, KIR2DL4 is differentially expressed in 10, with the highest sampling consensus in KIRC. Additionally, KIR2DL4 RNA expression shows 12,141 significant gene co-expression associations, with the highest sampling consensus in THYM. Together, these results highlight SKCM, KIRC, and THYM as cancer lineages where KIR2DL4 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for KIR2DL4 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes KIR2DL4 survival associations across molecular data types. KIR2DL4 RNA expression shows survival associations in the most cancer types (30), followed by mutation status (3). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible KIR2DL4 RNA expression–survival associations across cancer types. High KIR2DL4 expression shows unfavorable associations in KIRP and UVM, but favorable associations in SKCM, UCEC, READ and BLCA. The SKCM Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify SKCM as the clearest survival context for KIR2DL4 RNA expression.
This table summarizes KIR2DL4 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 10. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for KIR2DL4. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. KIR2DL4 shows lower tumor expression in COAD and higher tumor expression in KIRC, HNSC, STAD, BRCA and BLCA. The KIRC box plot shows higher KIR2DL4 RNA expression in tumor versus normal tissue (log2 FC = +0.883, t-test p < 0.001).
This table shows molecular features associated with KIR2DL4 in patient tissues and cancer cell lines. In patient samples, KIR2DL4 shows the broadest associations at the RNA and protein expression levels, with THYM recurring as the lineage with the largest associated feature set. In cancer cell lines, KIR2DL4 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in KIDNEY, while CRISPR and shRNA rows add functional-dependency signals in UPPER_AERODIGESTIVE_TRACT and BLOOD_Lymphoma.
